Publications by authors named "S J Cleator"
Purpose: Here, we report the sensitivity of a personalized, tumor-informed circulating tumor DNA (ctDNA) assay (Signatera) for detection of molecular relapse during long-term follow-up of patients with breast cancer.
Methods: A total of 156 patients with primary breast cancer were monitored clinically for up to 12 years after surgery and adjuvant chemotherapy. Semiannual blood samples were prospectively collected, and analyzed retrospectively to detect residual disease by ultradeep sequencing using ctDNA assays, developed from primary tumor whole-exome sequencing data.
Article Synopsis
- The Hammersmith Score (HS) is a validated prognostic tool that helps predict response and survival rates in early-phase cancer trial participants based on routine biochemical measures.
- A study analyzed 212 patient referrals, finding that HS significantly predicted overall survival and outperformed the Royal Marsden Score (RMS) in its predictive ability.
- HS offers a simple and cost-effective method to improve patient selection and referral for early-phase cancer trials, especially in the context of modern cancer immunotherapy.
Sleep timing varies between individuals and can be altered in mental and physical health conditions. Sleep and circadian sleep phenotypes, including circadian rhythm sleep-wake disorders, may be driven by endogenous physiological processes, exogeneous environmental light exposure along with social constraints and behavioural factors. Identifying the relative contributions of these driving factors to different phenotypes is essential for the design of personalised interventions.
View Article and Find Full Text PDFBackground: FAST-Forward aimed to identify a 5-fraction schedule of adjuvant radiotherapy delivered in 1 week that was non-inferior in terms of local cancer control and as safe as the standard 15-fraction regimen after primary surgery for early breast cancer. Published acute toxicity and 5-year results are presented here with other aspects of the trial.
Design: Multicentre phase III non-inferiority trial.